Search | IOVS | ARVO Journals

Showing 1 – 18 of 18

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Short-Term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP CSC) – A Randomized, Placebo-Controlled Study

Roger A Goldberg; Jeffrey S. Heier

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):782. doi:

ARVO Annual Meeting Abstract July 2018

Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema

Hugo Quiroz-Mercado; David S Boyer; Peter A Campochiaro; Jeffrey S. Heier; Peter K Kaiser; Julie Kornfield; Baruch D Kuppermann; Vicken H Karageozian; Hampar L Karageozian; Lisa Karageozian; John Y Park; Melvin Sarayba

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1960. doi:

ARVO Annual Meeting Abstract July 2018

First-in human study of SF0166 Topical Ophthalmic Solution in patients with diabetic macular edema

D. Edwards; David S Boyer; Peter K Kaiser; Jeffrey S. Heier; Ben Askew

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1961. doi:

ARVO Annual Meeting Abstract July 2018

Incidence of Vascularized Drusen in Non-Exudative Age-related Macular Degeneration using Spectral Domain Optical Coherence Tomography (OCT) Angiography

Chris Or; Jeffrey S. Heier; Namrata Saroj; A. Yasin Alibhai; Nadia K Waheed

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3229. doi:

ARVO Annual Meeting Abstract July 2018

Lampalizumab for geographic atrophy (GA) in age-related macular degeneration (AMD): pooled results of the Chroma and Spectri phase 3 randomized clinical trials (RCTs)

Dante Joseph Pieramici; Frank Holz; Jeffrey S. Heier; Srinivas R. Sadda; Brandon G Busbee; Emily Y. Chew; Paul Mitchell; Adnan Tufail; Christopher Brittain; Daniela Ferrara; Sarah Gray; Lee Honigberg; Jillian Martin; Barbara Tong; Jason Ehrlich; Neil M Bressler

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4948. doi:

ARVO Annual Meeting Abstract September 2016

ORBIT: A phase IV clinical study - lessons learned from patient selection criteria for ocriplasmin intravitreal injection

Brian C Joondeph; Jay S Duker; David S Boyer; Jeffrey S Heier; Peter K Kaiser; Mathew W MacCumber; Dante Joseph Pieramici

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4063. doi:

ARVO Annual Meeting Abstract September 2016

Topline Results From Prospective, Double-masked, Placebo Controlled Phase 2 Clinical Study Evaluating Luminate ® (ALG-1001) in Patients with Symptomatic Focal Vitreomacular Adhesion

Baruch D Kuppermann; David S Boyer; Peter K Kaiser; Jeffrey S Heier; Peter A Campochiaro; Hugo Quiroz-Mercado; Julia Kornfield; Lisa Karageozian; Mohamed A Genead; Hampar L Karageozian; Vicken H Karageozian

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract June 2015

Six-Month Results From the ORBIT Study: Ocriplasmin Research to Better Inform Treatment of Symptomatic Vitreomacular Adhesion

Jay S Duker; David S Boyer; Jeffrey S Heier; Peter K Kaiser; Mathew W MacCumber; Dante Joseph Pieramici

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1203. doi:

ARVO Annual Meeting Abstract June 2015

Clinical Proof-of-Concept Study of Oral Synthetic cis -Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision

David A Saperstein; Dante Joseph Pieramici; Kenneth N Sall; Jeffrey S Heier; David M Brown; David G Birch; Cecelia R Sanchez; Todd Klesert; Claire S Barnes; Ronald A Schuchard; RET IDA 02 Study Group

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3791. doi:

ARVO Annual Meeting Abstract April 2014

A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema

Mitchell G Brigell; Peter A Campochiaro; Raafay Sophie; Michael Tolentino; Daniel Miller; David Browning; David S Boyer; Jeffrey S Heier; Kevin Peters

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1757. doi:

ARVO Annual Meeting Abstract March 2012

Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration

Daniel B. Roth; Jeffrey S. Heier; Desmond Thompson; Yuhwen Soo; Robert Vitti; Namrata Saroj; Alyson J. Berliner; Georg Groeztbach; Olaf Sowade; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2042. doi:

ARVO Annual Meeting Abstract March 2012

Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 COPERNICUS Study

David M. Brown; Julia A. Haller; David S. Boyer; Jeffrey S. Heier; W. L. Clark; Alyson J. Berliner; Robert Vitti; Oliver Zeitz; Rupert Sandbrink

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):936. doi:

ARVO Annual Meeting Abstract April 2011

Double-dose Ranibizumab For Choroidal Neovascularization Associated With Age-related Macular Degeneration Minimally Responsive To Prior Anti-Vascular Endothelial Growth Factor Treatment

Jeffrey Chang; Jeffrey S. Heier

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3543. doi:

ARVO Annual Meeting Abstract April 2011

Single Ascending Doses of DARPin®, MP0112, Show Potential for Quarterly Dosing in DME

Manjula Patel; Brian B. Berger; Jeffrey S. Heier; David M. Brown; Peter A. Campochiaro; Michael T. Stumpp

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):582. doi:

ARVO Annual Meeting Abstract April 2011

Efficacy of Dexamethasone Intravitreal Implant for Best Corrected Visual Acuity in Patients With Retinal Vein Occlusion After 7 Days

Baruch D. Kuppermann; Julia A. Haller; Francesco Bandello; Rubens Belfort, Jr.; Anat Loewenstein; Mark Gillies,; Jeffrey S. Heier; Jenny Jiao; Xiao-Yan Li; Scott M. Whitcup

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3966. doi:

ARVO Annual Meeting Abstract April 2011

Aggressive Anti-VEGF Treatment is Necessary to Control Diabetic Macular Edema in Many Patients: Month 36 Outcomes of the READ2 Trial

Diana V. Do; Quan D. Nguyen; Afsheen A. Khwaja; Roomasa Channa; Yasir J. Sepah; David S. Boyer; Jeffrey S. Heier; Jennifer I. Lim; Peter A. Campochiaro; READ 2 Study Group

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5332. doi:

ARVO Annual Meeting Abstract April 2011

VEGF Trap-Eye In CRVO: Primary Endpoint Results Of The Phase 3 COPERNICUS Study

Julia A. Haller; David S. Boyer; Jeffrey S. Heier; David M. Brown; Lloyd Clark; Robert Vitti

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):6643. doi:

Physiology and Pharmacology February 2010

Assessment of the Integrin α5β1 Antagonist JSM6427 in Proliferative Vitreoretinopathy Using In Vitro Assays and a Rabbit Model of Retinal Detachment

PDF

Grit Zahn; Kristine Volk; Geoffrey P. Lewis; Dörte Vossmeyer; Roland Stragies; Jeffrey S. Heier; Paul E. Daniel, Jr; Anthony P. Adamis; Ethan A. Chapin; Steven K. Fisher; Frank G. Holz; Karin U. Löffler; Jochen Knolle
TAGS: integrins, tissue membrane, oryctolagus cuniculus, retinal detachment, vitreoretinopathy, proliferative, antagonists
Invest. Ophthalmol. Vis. Sci.. 2010; 51(2):1028-1035. doi: 10.1167/iovs.09-3575

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Short-Term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP CSC) – A Randomized, Placebo-Controlled Study

Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema

First-in human study of SF0166 Topical Ophthalmic Solution in patients with diabetic macular edema

Incidence of Vascularized Drusen in Non-Exudative Age-related Macular Degeneration using Spectral Domain Optical Coherence Tomography (OCT) Angiography

Lampalizumab for geographic atrophy (GA) in age-related macular degeneration (AMD): pooled results of the Chroma and Spectri phase 3 randomized clinical trials (RCTs)

ORBIT: A phase IV clinical study - lessons learned from patient selection criteria for ocriplasmin intravitreal injection

Topline Results From Prospective, Double-masked, Placebo Controlled Phase 2 Clinical Study Evaluating Luminate ® (ALG-1001) in Patients with Symptomatic Focal Vitreomacular Adhesion

Six-Month Results From the ORBIT Study: Ocriplasmin Research to Better Inform Treatment of Symptomatic Vitreomacular Adhesion

Clinical Proof-of-Concept Study of Oral Synthetic cis -Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision

A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema

Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration

Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 COPERNICUS Study

Double-dose Ranibizumab For Choroidal Neovascularization Associated With Age-related Macular Degeneration Minimally Responsive To Prior Anti-Vascular Endothelial Growth Factor Treatment

Single Ascending Doses of DARPin®, MP0112, Show Potential for Quarterly Dosing in DME

Efficacy of Dexamethasone Intravitreal Implant for Best Corrected Visual Acuity in Patients With Retinal Vein Occlusion After 7 Days

Aggressive Anti-VEGF Treatment is Necessary to Control Diabetic Macular Edema in Many Patients: Month 36 Outcomes of the READ2 Trial

VEGF Trap-Eye In CRVO: Primary Endpoint Results Of The Phase 3 COPERNICUS Study

Assessment of the Integrin α5β1 Antagonist JSM6427 in Proliferative Vitreoretinopathy Using In Vitro Assays and a Rabbit Model of Retinal Detachment

To View More...

You must be signed into an individual account to use this feature.